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Background: Earlier kinetics of serum HCV core antigen (HCVcAg) and its predictive value on sustained virological
response (SVR) were investigated in patients with genotype 1 HCV infection during antiviral treatment.
Methods: In a multi-centered, randomized and positive drug-controlled phase IIb clinical trial on type Y peginterferon
α-2b (NCT01140997), forty-eight CHC patients who participated in pharmacokinetics were randomly divided into 4
cohorts and treated with PegIFNα (type Y peginterferon α-2b 90 μg, 135 μg, 180 μg and PegIFNα-2a 180 μg,
respectively, once a week) and ribavirin (< 75 kg, 1000 mg daily and ≥ 75 kg, 1200 mg daily) for 48 weeks, and
then followed up for 24 weeks. 32 patients infected with genotype 1 HCV and completed the whole process were
included in this study. HCV RNAs were detected at baseline, and weeks 4, 12, 24, 48 and 72 using Cobas TaqMan.
ARCHITECT HCVcAg was performed at 24, 48, 72, 96, 120 and 144 h in addition to the above time points. The receiver
operating curves (ROCs) were performed to study the predictive values of HCVcAg decline on SVR.
Results: Following antiviral treatment, serum HCVcAg levels rapidly declined within the first week and correlated
well with corresponding HCV RNA at baseline, weeks 4, 12, 24, 48 and 72 (rs = 0.969, 0.928, 0.999, 0.983, 0.985 and
0.946, respectively, P < 0.001). All of the areas under the receiver operating curves (AUROCs) were more than 0.80
and showed good predictive power on SVR at 24, 48, 72, 96, 120 and 144 h. The144 h was the best predictive time
point of HCVcAg decline on SVR because of its largest AUROC (more than 0.90).
Conclusions: Early kinetics of serum HCVcAg predicts SVR very well in genotype 1 CHC patients during antiviral
treatment, and its reduction value at 144 h is an earlier and stronger predictor on SVR than rapid virological
response and early virological response. (TRN: NCT01140997).
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In the past 10 years, treatment response of chronic
hepatitis C (CHC) has been increasingly improved based
on the combination of pegylated interferon (PegIFN) α
and ribavirin. The standard of care for newly diagnosed
patients with hepatitis C virus (HCV), administered for* Correspondence: weilai@pkuph.edu.cn
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unless otherwise stated.24 or 48 weeks, yielded sustained virological response
(SVR) in approximately 80% and 40-50% of patients in-
fected with HCV genotypes 2–3 and 1, respectively [1].
However, about 50% genotype 1 chronic hepatitis C
patients, who are the most common worldwide, do not
achieve SVR. Additionally, besides expensive costs,
almost all patients treated with PegIFNα and ribavirin
experience one or more adverse events during the
course of therapy [2]. As such, it is very important to
predict the virological response patterns before and
during anti-viral therapy.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sociated with the response to IFN-α-based therapy. Ini-
tial viral kinetics is most helpful in predicting treatment
outcome. Patients who achieved a rapid virological re-
sponse (RVR), which is defined as undetectable HCV
RNA by Week 4 of therapy, are very likely to achieve
SVR. By contrast, those who still have detectable HCV
RNA levels by Week 12 of therapy have a very low likeli-
hood of obtaining SVR [3,4]. As an illustration of the
point which early viral responses are influenced by all
pretreatment factors, once treatment has started, the
IL28B genotype loses predictive value for SVR [5,6].
Treatment duration should be tailored to the virological
response at weeks 4 and 12, and eventually week 24.
Treatment for all HCV genotypes should be stopped
at week 12, if the HCV RNA decline is less than 2
log10 IU/ml and at week 24, if HCV RNA is still detect-
able (≥50 IU/ml) [7]. That is to say, some patients do not
know whether they need stopping antiviral treatment or
keep going until week 24. Additionally, positive predictive
value (PPV) of RVR is high, but its negative predictive
value (NPV) is low. Marcellin et al. found that SVR can be
achieved in 88% of patients with undetectable HCV RNA
and 43% of those with detectable HCV RNA at week 4 [8].
Therefore, it is very important to search for a new marker
for that will predict SVR earlier and more accurately.
Quantitative detection of HCV core antigen (HCVcAg)
may be an alternative, which was reported to confirm viral
replication in hepatitis C infected patients [9,10]. Several
studies showed that levels of serum HCVcAg correlate
with those of HCV RNA in CHC patients [11-13]. In acute
hepatitis C cases, HCVcAg can pick up a great majority of
HCV RNA positive samples [14], and closely track HCV
RNA dynamics throughout the course of the disease.
Moreover, a sharp and parallel decrease of HCV RNA dy-
namics was observed during treatment with antiviral drugs
3 months after onset [15]. In the current study, based on a
phase IIb clinical trial that examined the safety and efficacy
of type Y pegylated interferon alfa-2b (NCT01140997,
Pegabin®, Tebao Pharmaceuticals Inc., China) in CHC pa-
tients, we characterized dynamic changes of HCVcAg
levels in patients with genotype 1 HCV infection during
antiviral treatment and investigated the predictive value of
earlier kinetics of serum HCVcAg on SVR.
Methods
Study design
The clinical trial, based by the current study, was multi-
centered, randomized, open-labeled and used a positive
drug-control on 210 naïve patients with HCV infection.
The patients were randomly divided into 4 cohorts and
treated with PegIFNα (type Y PegIFN α-2b 90 μg, 135 μg,
180 μg and PegIFNα-2a 180 μg, respectively, once a week)
and ribavirin (< 75 kg, 1000 mg daily and ≥ 75 kg, 1200 mgdaily) for 48 weeks, and then followed up for 24 weeks.
Among all 48 CHC patients who participated in pharma-
cokinetics, only those infected with genotype 1 HCV and
who completed the whole process were included in this
study.
Inclusion and exclusion criteria
The patients ranged in age from 18 to 65 years old, had
positive anti-HCV and HCV RNA levels of greater than
2000 IU/ml for at least six months, and also provided
evidence of written informed consent. The study was
approved by the ethical committees of Peking University
People’s Hospital, Peking University First Hospital, Beijing
Friendship Hospital, 302 Hospital of People’s Liberation
Army, Beijing Youan Hospital, First Affiliated Hospital of
Jilin University, Central-south University Xiangya Hospital,
Sichuan University West China Hospital, Chongqing
Medical University Second Affiliated Hospital, Fuzhou
Infectious Disease Hospital, Guangzhou Eighth People’s
Hospital, Nangfang Hospital, the First Affiliated Hospital
of Guangxi Medical Universtiy, the Second Affiliated
Hospital of Harbin Medical University, the First Affiliated
Hospital of Anhui Medical University, Jinan Infectious
Disease Hospital, the First Affiliated Hospital of Lanzhou
University, the First Affiliated Hospital of Nanchang
University, 81 Military Hospital, Jiangsu Provincial People’s
Hospital, the Second Hospital of Nanjing, Changhai
Hospital of Shanghai, Shanghai Public Health Clinical
Center, Renji Hospital of Shanghai, 85 Hospital of People’s
Liberation Army, Ruijin Hospital of Shanghai, Huashan
Hospital of Shanghai, Shenzhen Third People’s Hospital,
the Third Affiliated Hospital of Hebei Medical University,
the First Affiliated Hospital of Shanxi University, Tianjin
Third Central Hospital, the First Affiliated Hospital
of Wenzhou Medical College, Huazhong Science and
Technology University Tongji Hospital, Tangdu Hospital,
the First Affiliated Hospital of Zhengzhou University and
Henan Provincial People’s Hospital. The study protocol
conformed to the ethical guidelines of the 1975 Declaration
of Helsinki, and was performed according to the guidelines
of the International Conference on Harmonization for
Good Clinical Practice. Exclusion criteria included signifi-
cantly abnormal liver function (for example total bilirubin
levels greater than 2 ULN, albumin levels lower than
35 g/L, PTA levels lower than 60% or evidence of decom-
pensated liver disease and hepatocarcinoma), pregnancy
or inability to practice adequate contraception, significant
systemic or major illnesses other than liver disease, pre-
existing lower blood cells (white blood cell levels lower
than 3 × 109/L, absolute neutrocyte counts lower than
1.5 × 109/L, platelet levels lower than 90 × 109/L and
hemoglobin lower than lower limit of normal (LLN) or
known history of antiviral or immunosuppressive ther-
apy, and evidence of other viruses infection such as HAV,
Table 1 Baseline patient characteristics for patients with
sustained virological response (SVR) and non-sustained
virological response (N-SVR)
Parameters SVR N-SVR P
Male/female 10/6 6/10 0.325
Age (years) 41.90 ± 11.08 51.36 ± 8.31 0.019
ALT (U/L) 47.38 ± 3.65 47.27 ± 6.87 0.988
HCV RNA (log10 IU/mL) 6.39 ± 0.57 6.21 ± 1.14 0.557
HCVcAg (log10 fmol/L) 3.61 ± 0.54 3.75 ± 0.36 0.441
No. of each cohortsa 6/3/7/5 2/6/2/1 0.057
aThe numbers of patients in each cohorts (Y PegIFN α-2b 90 μg, 135 μg,
180 μg, and PegIFNα-2a 180 μg).
Figure 1 Dynamic changes of HCVcAg and HCV RNA levels
during antiviral treatment. Following antiviral treatment, serum
HCVcAg levels closely track those of HCV RNA and rapidly declined
within the first 4 weeks.
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other agents was excluded, for example alcohol, drug,
auto-immunity and metabolic abnormality among others.
Lab examination
HCV RNA levels were measured at baseline, at weeks 4,
12, 24, 48 and 72 of therapy. The COBAS AmpliPrep/
COBAS TaqMan automated real-time polymerase chain
reaction (PCR) platform (Roche Molecular Systems,
Pleasanton, CA) was used. This assay has a lower limit
of detection (LLOD) of 15 IU/mL and a lower limit of
quantification of 43 IU/mL.
The ARCHITECT HCVcAg (Abbott Diagnostics,
Wiesbaden, Germany), which is a quantitative chemilu-
minescent microparticle immunoassay and run on the fully
automated ARCHITECT instrument, was used to quantify
HCVcAg. As the manufacturer instructed, the assay was
performed and HCVcAg levels lower than 3.0 fmol/l were
considered nonreactive. ΔHCVcAg was defined as a log10
reduction of serum HCVcAg levels between other time
points and baseline.
Definitions
SVR was defined as an undectable HCV RNA level
(<50 IU/ml), 24 weeks after cessation of treatment. RVR
was defined as undetectable HCV RNA in a sensitive assay
(lower limit of detection ≤ 50 IU/ml) at week 4 of therapy
and maintained up to the end of treatment [7]. The SVR
corresponds to a cure of infection in > 99% of cases [16].
ΔHCVcAg was defined as a log10 reduction of serum
HCVcAg levels between other time points and baseline.
Statistical analysis
The statistical significance of differences between groups
was analyzed by the student’s t-test, one-way ANOVA,
Fisher’s exact test or the Mann–Whitney U-test. Correl-
ation between HCVcAg and HCV RNA levels was mea-
sured using the Spearman’s correlation coefficient. The
optimal predictive values of ΔHCVcAg and HCVcAg at
different time points were assessed by calculating the
areas under the univariate receiver operating characteris-
tics (AUROC) curve. Sensitivity, specificity, PPV, and
NPV were analyzed to determine the reliability of pre-
dictors of the response to therapy. All statistical analyses
were performed with SPSS 16.0 (Chicago, IL, USA).
Two-tailed P values less than 0.05 were considered sig-
nificant statistically.
Results
Baseline characteristics of sample
All thirty-two patients included in this study were in-
fected with genotype 1b HCV. There were 16 male and
16 female patients. The mean age was 45.16 ± 11.06.
Mean baseline viral load and HCV antigen levels were6.33 ± 0.88 log10 IU/mL and 3.66 ± 0.49 log10 fmol/L,
respectively. Based on the outcomes, these patients were
divided into SVR and non-SVR groups, of which the
baseline characteristics are described below (Table 1).
There were no differences between SVR and non-SVR
groups in baseline parameters including gender, ALT,
HCV RNA, HCVcAg, dose and category of PegIFNα and
excluding age.
Dynamic changes of HCVcAg levels during antiviral
treatment
Following antiviral treatment, serum HCVcAg levels
closely track those of HCV RNA and rapidly declined
within the first 4 weeks (Figure 1). At baseline, week 4,
8, 12, 24, 48 and 72, HCVcAg levels showed excellent
correlation with HCV RNA; spearman correlation coeffi-
cients were 0.956, 0.937, 0.999, 0.983, 0.995 and 0.980,
respectively (P < 0.001).
Predictive values of ΔHCVcAg on SVR at various time
points of the first 12 weeks of treatment
To investigate the predictive values of ΔHCVcAg at vari-
ous time points within the first 12 weeks on SVR and to
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(Figure 2). Based on these ROCs, important parameters
were worked out including AUROC, the optimal cutoff
values, sensitivity, specificity, PPV and NPV (Table 2).
AUROCs were 0.835, 0.814, 0.870, 0.866, 0.879, 0.913,Figure 2 ROCs of predictive values of ΔHCVcAg at various time point
0.870, 0.866, 0.879, 0.913, 0.853, 0.823 and 0.719 at 24 h, 48 h, 72 h, 96 h, 120.853, 0.823 and 0.719 at 24 h, 48 h, 72 h, 96 h, 120 h
and 144 h, and at weeks 4, 8 and 12. The highest
AUROC was 0.913 at 144 h. At 24 h, 48 h, 72 h, 96 h,
120 h and 144 h, and at week 4, cutoff values, which
predicted SVR, were 0.785, 1.090, 1.034, 1.262, 1.138,s of the first 12 weeks on SVR. AUROCs calculated were 0.835, 0.814,
0 h, 144 h, and weeks 4, 8, 12.
Table 2 Area under the ROC curve (AUROC), sensitivity, specificity, and predictive values of sustained virological
response based on a log 10 decrease in total HCV core antigen, across cutpoints and timepoints after initial antiviral
treatment
24 h 48 h 72 h 96 h 120 h 144 h - 1 144 h - 2 4 w 8 w 12 w
AUROC 0.835 0.814 0.870 0.866 0.879 0.913 0.913 0.853 0.823 0.719
(95% CI) (0.691-0.980) (0.663-0.965) (0.742-0.998) (0.738-0.994) (0.760-0.998) (0.799-1.000) (0.799-1.000) (0.720-0.985) (0.680-0.965) (0.520-0.917)
Cutoffa 0.785 1.090 1.034 1.262 1.138 0.976 1.096 3.231 3.780 3.770
Sensitivity 0.810 0.762 0.810 0.810 0.810 0.952 0.762 0.714 0.667 0.667
Specificity 0.818 0.727 0.818 0.818 0.818 0.700 0.800 0.909 1.000 0.818
PPV 1.000 1.000 1.000 1.000 1.000 0.913 1.000 1.000 1.000 1.000
NPV 0.846 0.846 0.846 0.846 0.846 1.000 0.769 0.687 0.611 0.687
AUROC, areas under the univariate receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value.
aCutoff was defined as change of log 10 fmol/L.
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0.762, 0.810, 0.810, 0.818, 0.762 and 0.714; specificity was
0.818, 0.727, 0.818, 0.818, 0.818, 0.800 and 0.909; PPVs
were 1.000, 1.000, 1.000, 1.000, 1.000, 1.000 and 1.000; and
NPVs were 0.846, 0.846, 0.846, 0.846, 0.846, 0.769 and
0.688, respectively. While PPVs were similar across time
points, NPVs differed. The optimal combination of
AUROC, PPV and NPV, with a cutoff value of 0.976 was at
144 h, with AUROC 0.913, PPV of 0.913 and NPV 1.000.
Predictive power of HCVcAg on SVR at various time
points of the first week of the treatment
Predictive values of HCVcAg on SVR were measured
using by AUROCs at 24 h, 48 h, 72 h, 96 h, 120 h and
144 h. The corresponding AUROCs were 0.236, 0.225,
0.195, 0.186, 0.182 and 0.126 at these various timeFigure 3 ROC curves of predictive values of HCV RNA at week 4
on sustained virological response (SVR). When the optimal cutoff
value was 3.770, the corresponding AUROC was 0.854 (95%
CI 0.705-1.000).points, respectively. This showed that the absolute values
of HCVcAg levels had no predictive power on SVR in
genotype 1 HCV infected patients.
Predictive value of HCV RNA decline at week 4 of the
treatment on SVR
ROC was performed on the basis of the relationship between
ΔHCV RNA at week 4 and SVR (Figure 3). When the cutoff
value was 3.770, the corresponding AUROC, sensitivity, spe-
cificity, PPV and NPV were 0.854 (95% CI 0.705-1.003),
0.850, 0.833, 1.000 and 0.706. Calculated sensitivity, specifi-
city, accuracy, PPV and NPV of RVR were 0.229, 1.000,
0.500, 1.000 and 0.407. Table 3 showed the results compar-
ing the predictive value of ΔHCVcAg at 144 h, and weeks 4,
8, and 12 to that of ΔHCV RNA at week 4. Results indicated
comparable PPVs, both 100%, but higher NPV (76.9%) and
higher AUROC (0.913) for HCVcAg at 144 h compared to
HCV RNA at week 4 (70.6%, 0.854) respectively.
Comparison of predictive power between a log10
decrease in HCVcAg at 144 h and RVR/EVR
As for the 32 patients included in this study, the param-
eters of predictive value of a log10 decrease in HCVcAgTable 3 Predictive values and Area under the ROC curve
(AUROC) of sustained virological response based on a log
10 decrease in total HCV core antigen and HCV RNA
concentrations after initial antiviral treatment
PPV NPV AUROC (95% CI)
ΔHCVcAg (log10 fmol/L)
144 h 100% 76.9% 0.913 (0.799-1.000)
Week 4 100% 68.7% 0.853 (0.720-0.985)
Week 8 100% 61.1% 0.823 (0.680-0.965)
Week 12 100% 68.7% 0.719 (0.520-0.917)
ΔHCV RNA (log10 IU/mL)
Week 4 100% 70.6% 0.854 (0.705-1.000)
PPV, positive predictive value; NPV, negative predictive value; AUROC, areas
under the univariate receiver operating characteristic curve.
Table 4 Comparison of predictive power of a log10 decrease
in HCVcAg at 144 h and rapid virological response
(RVR)/early virological response (EVR)
Sensitivity Specificity Accuracy PPV NPV
ΔHCV Ag ≥ 1 log 0.952 0.727 0.875 0.870 0.889
RVR 0.286 1.000 0.531 1.000 0.423
EVR 1.000 0.273 0.750 0.724 1.000
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calculated (Table 4). RVR had higher specificity (1.000)
and PPV (1.000), and EVR has higher sensitivity (1.000)
and NPV (1.000). Conversely, sensitivity and NPV of
RVR, and specificity and PPV of EVR were lower. The
accuracy of RVR and EVR was lower than a log10 de-
crease of HCVcAg at 144 h.
Influence of baseline parameters on ΔHCVcAg at 144 h
As indicated in Figure 4, a decline of HCVcAg at 144 h
showed a correlation with age (rs = −0.583, P < 0.001),
and no correlation with baseline viral loads and
HCVcAg levels (P = 0.107 and P = 0.288, respectively).
Additionally, gender, dose and category of PegIFNα
had no effect on ΔHCVcAg at 144 h (P = 0.276, P = 0.458
and P = 0.623, respectively).
Discussion
Several assays are used in the screening, diagnosis and
management of HCV infection: detection of specific
antibody to HCV and HCV RNA, and HCV genotyping
[17,18]. So far, the early dynamic change of HCV nucleic
acid levels, which are direct proof of viral replication, is
a very important marker in predicting antiviral response
patterns in CHC patients. As a gold standard, the kinetics
of HCV RNA has been widely used in response-guided
and individual therapy. Conjeevaram et al. thought that
viral kinetics provide a summative reflection of the baseline
factors, including insulin resistance, gender, age and gen-
etic polymorphisms, which are involved in transducing theFigure 4 Influence of baseline parameters on ΔHCVcAg at 144 h. Dec
P < 0.001), and no correlation with baseline viral loads and HCVcAg levels (response to these agents [19]. However, as described above,
nucleic acid quantitative detection of LOD of 50 IU/mL
has some limitations, especially in developing countries.
The first assay for HCVcAg was developed in 1999
[20]. Now sensitivity and specificity of quantitative
HCVcAg assay has been increasingly improved. The
Architect HCVcAg assay (Abbott Diagnostics), with a dy-
namic range of quantification (3.0 – 20,000 fmol/L), is
commercially available. It shows a good correlation with
HCV RNA in various CHC populations including HCV
monoinfection, HCV/HIV and HCV/HBV coinfection,
and can reflect viral replication as HCV RNA does [21].
Here, similar changes of HCVcAg and HCV RNA were
observed during PegIFNα combined with ribavirin treat-
ment in genotype 1 HCV infected patients. Good correla-
tions were showed between serum HCVcAg and HCV
RNA levels at various time points observed in this study.
Moreover, serum HCVcAg levels declined sharply in the
first 4 weeks after treatment was initiated.
By calculating the AUROCs, we assessed the optimal
predictive values of ΔHCVcAg at 24, 48, 72, 96, 120 and
144 h on SVR. We found that all of AUROCs were more
than 0.80 and showed good predictive power at various
time points in the first week. The second injection was
performed at 168 h. We selected 144 h, which had the
largest AUROC (0.913) as the best predictive time point.
On the other hand, for obtaining the highest sensitivity
and NPV, the lowest cutoff was obtained at quartile 0.25.
Conversely, for obtaining the highest specificity and
PPV, the highest cutoff was obtained at quartile 0.75. So,
we selected 0.976 and 1.096 as cutoff values of 144 h,
which both had a corresponding NPV and PPV of 1.000.
That is, at the 144 h time point it will be unlikely that
patients will have a ΔHCVcAg lower than 0.976 and
those patients with a ΔHCVcAg of more than 1.096 will
be likely to achieve SVR. On the other hand, if the
ΔHCVcAg at 144 h is between 0.976 and 1.096, the cor-
responding NPV and PPV will be at least 0.769 and
0.913, respectively.line of HCVcAg at 144 h showed a correlation with age (rs = −0.583,
P = 0.107 and P = 0.288, respectively).
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strong correlation (r = 0.86), from a sample where
plasma HCV antigen was detected in 51 of 54 patients
with an interpolated LOD cut off between 103 and 104
RNA IU/mL [22]. Chevaliez et al. thought the current
assays for detecting HCVcAg are not suitable for moni-
toring changes of HCV replication power during antiviral
therapy and response-guided therapy [10]. However, the
hypothesis has never been proven in clinical practice. In
the current study, we analyzed the predictive power of
ΔHCV RNA at week 4 and RVR on SVR by ROC. The
AUROC of ΔHCV RNA at week 4 was lower than that of
ΔHCVcAg at 144 h. RVR which accuracy was 50% had
higher PPV and lower NPV. We thought that the sensitiv-
ity of HCVcAg detection may be lower than that of HCV
RNA when confirming viral replication and active infec-
tion, but HCVcAg may actually be more meaningful in
reflecting dynamic changes of viral replication and in pre-
dicting SVR earlier during double treatment. If proven
true by larger patient samples, HCVcAg detection will be
more promising in clinical practice because it is less ex-
pense and easier to perform, especially in areas with lim-
ited resources.
As we well know, many baseline parameters including
virus, host and drug factors are associated with response
to IFN-α-based therapy. In the current study, we found
that patient gender, dose and category of PegIFNα, base-
line viral loads and HCVcAg levels had no correlation
with ΔHCVcAg at 144 h, except for age. Further investi-
gation should be performed to determine whether it is
true or limited by numbers of patients. On the other
hand, we did not differentiate null responders and re-
lapsers because of limited receivers.
Conclusions
Serum HCVcAg is a good marker for reflecting dynamic
changes of HCV viremia in genotype 1 CHC patients
during PegIFNα when combined with ribavirin treat-
ment. Following antiviral treatment, serum HCVcAg
levels rapidly declined within the first week similar to
HCV RNA. All of the AUROCs were more than 0.80 and
showed good predictive power on SVR at 24, 48, 72, 96,
120 and 144 h. 144 h was selected as the best predictive
time point because of its largest AUROC (more than
0.90). 0.976 and 1.096 were selected as cutoff values of
144 h; both have a corresponding NPV and PPV of 1.000.
Moreover, the predictive value of ΔHCVcAg at 144 h is
better than that of ΔHCV RNA and negative HCV RNA
at week 4.
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